ArticleProceedings of the National Academy of Sciences of the United States of America2017
Albendazole and antibiotics synergize to deliver short-course anti-
Article in Proceedings of the National Academy of Sciences of the United States of America, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 1 synthesis or guideline pooled it, 56 citations in OpenAlex.
- Factors associated with variation in single-dose albendazole pharmacokinetics: A systematic review and modelling analysis.PLoS neglected tropical diseases · 2022Pooled it
- Assessing the efficacy of high-dose rifampicin plus albendazole against onchocerciasis.PLoS neglected tropical diseases · 2026Trial
- High-Dose Rifampicin Plus Albendazole Rapidly Clears Lymphatic Filariasis Circulating Filarial Antigen in a Randomised Clinical Trial: A Promising Step Toward Short-Course Macrofilaricidal Therapy.Pathogens (Basel, Switzerland) · 2026Trial
- Secreted filarial acetylcholine analogs modulate parasite reproduction and host physiology.Nature communications · 2026Article
- Onchocerciasis overview: pathogenesis, clinical spectrum, and therapeutic challenges of a neglected tropical disease.Frontiers in parasitology · 2026Review
- Fexinidazole and Corallopyronin A target Wolbachia-infected sheath cells present in filarial nematodes.PLoS pathogens · 2025Article
- Host environment shapes filarial parasite fitness and Wolbachia endosymbionts dynamics.PLoS pathogens · 2025Article
- Unraveling the Dynamics of Human Filarial Infections: Immunological Responses, Host Manifestations, and Pathogen Biology.Pathogens (Basel, Switzerland) · 2025Review
- Fexinidazole and Corallopyronin A targetbioRxiv : the preprint server for biology · 2025Article
- Combinations of the azaquinazoline anti-Frontiers in microbiology · 2024Article
- The cellular lives of Wolbachia.Nature reviews. Microbiology · 2023Review
- Miniature spatial transcriptomics for studying parasite-endosymbiont relationships at the micro scale.Nature communications · 2023Article
- Programmed cell death pathways as targets for developing antifilarial drugs: Lessons from the recent findings.Journal of cellular and molecular medicine · 2023Review
- Toward novel treatment against filariasis: Insight into genome-wide co-evolutionary analysis of filarial nematodes andFrontiers in microbiology · 2023Article
- A mouse infection model and long-term lymphatic endothelium co-culture system to evaluate drugs against adult Brugia malayi.PLoS neglected tropical diseases · 2022Article
- Molecular Docking Simulation Studies Identifies Potential Natural Product Derived-Antiwolbachial Compounds as Filaricides against Onchocerciasis.Biomedicines · 2021Article
- Advances in preclinical platforms ofFrontiers in tropical diseases · 2021Article
- Dual RNAseq analyses at soma and germline levels reveal evolutionary innovations in the elephantiasis-agent Brugia malayi, and adaptation of its Wolbachia endosymbionts.PLoS neglected tropical diseases · 2021Article
- Corallopyronin A for short-course anti-wolbachial, macrofilaricidal treatment of filarial infections.PLoS neglected tropical diseases · 2020Article
- The endosymbiont Wolbachia rebounds following antibiotic treatment.PLoS pathogens · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 1 institution in 1 country.
Funding
Abstract
Elimination of filariasis requires a macrofilaricide treatment that can be delivered within a 7-day period. Here we have identified a synergy between the anthelmintic albendazole (ABZ) and drugs depleting the filarial endosymbiont
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.